Further Delineation of Pyridoxine-Responsive Pyridoxine Phosphate Oxidase Deficiency Epilepsy: Report of a New Case and Review of the Literature With Genotype-Phenotype Correlation

Abstract

In recent years, the clinical spectrum of pyridoxine phosphate oxidase (PNPO) deficiency has broadened. There are a growing number of patients with a transient or lasting response to pyridoxine in addition to cases that respond more traditionally to pyridoxal-phosphate. However, among pyridoxine-responsive patients with PNPO gene mutation, there are only a few reports on electroencephalogram (EEG) ictal/interictal patterns, and data regarding the outcomes are inconsistent. We describe a case of neonatal onset epilepsy with missense mutation c(674G>A) p(R225 H) in PNPO gene and pyridoxine responsiveness. Comparing this patient with 24 cases of previously described pyridoxine-responsive pyridoxine phosphate oxidase deficiency epilepsy, we found that patients carrying the missense mutation c(674G>A) p(R225 H) of the PNPO gene might have a more severe epileptic phenotype, possibly because of their lower residual PNPO activity. Indeed, pyridoxine-responsive pyridoxine phosphate oxidase deficiency epilepsy remains a challenge, with neurodevelopmental disabilities occurring in about half of the cases.

Keywords

pyridoxine phosphate oxidase deficiency pyridoxine-dependent epilepsy

Get full access to this article

View all access options for this article.

References

Schmitt

Baumgartner

Mills

et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010;52(7):133–142.

Kuo

Wang

. Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine. Pediatr Neurol. 2002;26(2):146–147.

Mills

Robert

Michael

et al. Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 50-phosphate oxidase. Hum Mol Genet. 2005;14(8):1077–1086.

Pearl

Hyland

Chiles

et al. Partial pyridoxine responsiveness in PNPO deficiency. JIMD Rep. 2013;9:139–142.

Mills

Camuzeaux

Footitt

et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain. 2014;137:1350–1360.

Plecko

Paul

Mills

et al. Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology. 2014;82(16):1425–1433.

Guerin

Aziz

Mutch

et al. Pyridox(am)ine-5-phosphate oxidase deficiency treatable cause of neonatal epileptic encephalopathy with burst suppression: case report and review of the literature. J Child Neurol. 2015;30(9):1218–1225.

Gospe

Jr . Pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency: unique clinical symptoms and non-specific EEG characteristics. Dev Med Child Neurol. 2010;52(7):602–603.

Ware

Earl

Salomons

et al Typical and atypical phenotypes of PNPO deficiency with elevated CSF and plasma pyridoxamine on treatment. Dev Med Child Neurol. 2014;56(5):498–502.

10.

Levtova

Camuzeaux

Laberge

et al. Normal cerebrospinal fluid pyridoxal 5′-phosphate level in a PNPO-deficient patient with neonatal-onset epileptic encephalopathy. JIMD Rep. 2015;22:67–75.

11.

Di Salvo

Mastrangelo

Nogués

et al Biochemical data from the characterization of a new pathogenic mutation of human pyridoxine-5′-phosphate oxidase (PNPO). Data Brief. 2017;15:868–875.

12.

Jaeger

Abeling

Salomons

et al. Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation. Mol Genet Metab Rep. 2016;6:60–63.

13.

Nabbout

Souzet

Plouin

et al. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal. 1999;81:125–129.

14.

Bok

Maurits

Willemsen

. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. Epilepsia. 2010;51(12):2406–2411.

15.

Bok

Halbertsma

Houterman

et al. Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol. 2012;54:849–854.